₹522*
MRP ₹580
10% off
₹493*
MRP ₹580
15% CB
₹87 cashback(15%)
Free Delivery
With Circle membership
(Inclusive of all Taxes)
This offer price is valid on orders above ₹800. Apply coupon PHARMA10/PHARMA18 (excluding restricted items)
Prescription drugWhats That
Composition
BRINZOLAMIDE
Consume Type
OPHTHALMIC
Return Policy
3 Days Returnable
Expires on or after
Apr-24
for this medicine
Drug-Drug Interactions
BrinzolamideAspirin
Severe
BrinzolamideSalsalate
Severe
Drug-Drug Interactions
Login/Sign Up
BrinzolamideAspirin
Severe
How does the drug interact with Brinzagan Ophthalmic Suspension 5 ml:
Coadministration of Brinzagan Ophthalmic Suspension 5 ml with Aspirin may cause side effects.
How to manage the interaction:
Although there is a possible interaction between aspirin and Brinzagan Ophthalmic Suspension 5 ml, you can take these medicines together if prescribed by a doctor. However, if you experience ringing in your ears, headache, vomiting, dizziness, or palpitations, please contact a doctor. Do not stop using any medications without talking to a doctor.
Coadministration of Brinzagan Ophthalmic Suspension 5 ml with Aspirin may cause side effects.
How to manage the interaction:
Although there is a possible interaction between aspirin and Brinzagan Ophthalmic Suspension 5 ml, you can take these medicines together if prescribed by a doctor. However, if you experience ringing in your ears, headache, vomiting, dizziness, or palpitations, please contact a doctor. Do not stop using any medications without talking to a doctor.
BrinzolamideSalsalate
Severe
How does the drug interact with Brinzagan Ophthalmic Suspension 5 ml:
Concomitant use of Brinzagan Ophthalmic Suspension 5 ml with salsalate can increase the risk of side effects.
How to manage the interaction:
Although there is an interaction, Brinzagan Ophthalmic Suspension 5 ml should be used with salsalate only if prescribed by the doctor. Consult a doctor immediately if you experience ringing in the ears, vomiting, headache, dizziness, and fever. Do not stop using any medications without first talking to your doctor.
Concomitant use of Brinzagan Ophthalmic Suspension 5 ml with salsalate can increase the risk of side effects.
How to manage the interaction:
Although there is an interaction, Brinzagan Ophthalmic Suspension 5 ml should be used with salsalate only if prescribed by the doctor. Consult a doctor immediately if you experience ringing in the ears, vomiting, headache, dizziness, and fever. Do not stop using any medications without first talking to your doctor.
BrinzolamideCholine salicylate
Severe
How does the drug interact with Brinzagan Ophthalmic Suspension 5 ml:
Taking Brinzagan Ophthalmic Suspension 5 ml with Choline salicylate may increase the risk of side effects.
How to manage the interaction:
Although taking Brinzagan Ophthalmic Suspension 5 ml and Choline salicylate together can result in an interaction, they can be taken together if prescribed by a doctor. However, if you experience ringing in your ears, headache, vomiting, dizziness, or palpitations, consult a doctor. Do not stop using any medications without consulting a doctor.
Taking Brinzagan Ophthalmic Suspension 5 ml with Choline salicylate may increase the risk of side effects.
How to manage the interaction:
Although taking Brinzagan Ophthalmic Suspension 5 ml and Choline salicylate together can result in an interaction, they can be taken together if prescribed by a doctor. However, if you experience ringing in your ears, headache, vomiting, dizziness, or palpitations, consult a doctor. Do not stop using any medications without consulting a doctor.
BrinzolamideSodium salicylate
Severe
How does the drug interact with Brinzagan Ophthalmic Suspension 5 ml:
Concomitant use of Brinzagan Ophthalmic Suspension 5 ml with sodium salicylate may cause ringing in the ears, nausea, vomiting, headache, dizziness, confusion, hallucinations, rapid breathing, fever, and seizure (convulsions).
How to manage the interaction:
Although there is an interaction, Brinzagan Ophthalmic Suspension 5 ml should be used with sodium salicylate only if prescribed by the doctor. However, if you experience ringing in the ears, vomiting, headache, dizziness, or fever, contact your doctor immediately. Do not stop using any medications without consulting your doctor.
Concomitant use of Brinzagan Ophthalmic Suspension 5 ml with sodium salicylate may cause ringing in the ears, nausea, vomiting, headache, dizziness, confusion, hallucinations, rapid breathing, fever, and seizure (convulsions).
How to manage the interaction:
Although there is an interaction, Brinzagan Ophthalmic Suspension 5 ml should be used with sodium salicylate only if prescribed by the doctor. However, if you experience ringing in the ears, vomiting, headache, dizziness, or fever, contact your doctor immediately. Do not stop using any medications without consulting your doctor.
BrinzolamideDiflunisal
Severe
How does the drug interact with Brinzagan Ophthalmic Suspension 5 ml:
Coadministration of Brinzagan Ophthalmic Suspension 5 ml with diflunisal can increase the risk of side effects.
How to manage the interaction:
Although there is an interaction, Brinzagan Ophthalmic Suspension 5 ml should be used with diflunisal only if prescribed by the doctor. Consult a doctor if you experience vomiting, headache, dizziness, or fever. Do not stop using any medications without first talking to your doctor.
Coadministration of Brinzagan Ophthalmic Suspension 5 ml with diflunisal can increase the risk of side effects.
How to manage the interaction:
Although there is an interaction, Brinzagan Ophthalmic Suspension 5 ml should be used with diflunisal only if prescribed by the doctor. Consult a doctor if you experience vomiting, headache, dizziness, or fever. Do not stop using any medications without first talking to your doctor.
Drug-Food Interactions
No Drug - Food interactions found in our database. Some may be unknown. Consult your doctor for what to avoid during medication.
Drug-Food Interactions
Login/Sign Up
Drug-Diseases Interactions
BRINZOLAMIDE-1%W/VAgranulocytosis
Severe
BRINZOLAMIDE-1%W/VDisorders of porphyrin and bilirubin metabolism
Severe
Drug-Diseases Interactions
Login/Sign Up
BRINZOLAMIDE-1%W/VAgranulocytosis
Severe
How does the disease interact with Brinzagan Ophthalmic Suspension 5 ml:
Applying Brinzagan Ophthalmic Suspension 5 ml ophthalmic to the skin, eyes, or mucosal membranes may cause systemic absorption. In addition to methemoglobinemia, sulfhemoglobinemia, leukopenia, granulocytopenia, eosinophilia, hemolytic anaemia, aplastic anaemia, purpura, coagulation problem, thrombocytopenia, hypofibrinogenemia, and hypoprothrombinemia, the usage of sulfonamides has also been linked to hematologic damage. Patients who already have blood dyscrasias or marrow suppression should use topical sulfonamide therapy with caution. During prolonged therapy (>2 weeks), complete blood counts should be taken on a regular basis, and patients should be instructed to report any indications or symptoms of a blood dyscrasia right away, such as fever, sore throat, local infection, bleeding, pallor, dizziness, or jaundice.
How to manage the interaction:
Brinzagan Ophthalmic Suspension 5 ml should be administered cautiously in patients with preexisting blood problems or bone marrow suppression. Complete blood count tests are advised regularly during prolonged therapy (>2 weeks). Consult the doctor if you notice signs or symptoms of blood problems such as fever, sore throat, local infection, bleeding, dizziness, or jaundice.
Applying Brinzagan Ophthalmic Suspension 5 ml ophthalmic to the skin, eyes, or mucosal membranes may cause systemic absorption. In addition to methemoglobinemia, sulfhemoglobinemia, leukopenia, granulocytopenia, eosinophilia, hemolytic anaemia, aplastic anaemia, purpura, coagulation problem, thrombocytopenia, hypofibrinogenemia, and hypoprothrombinemia, the usage of sulfonamides has also been linked to hematologic damage. Patients who already have blood dyscrasias or marrow suppression should use topical sulfonamide therapy with caution. During prolonged therapy (>2 weeks), complete blood counts should be taken on a regular basis, and patients should be instructed to report any indications or symptoms of a blood dyscrasia right away, such as fever, sore throat, local infection, bleeding, pallor, dizziness, or jaundice.
How to manage the interaction:
Brinzagan Ophthalmic Suspension 5 ml should be administered cautiously in patients with preexisting blood problems or bone marrow suppression. Complete blood count tests are advised regularly during prolonged therapy (>2 weeks). Consult the doctor if you notice signs or symptoms of blood problems such as fever, sore throat, local infection, bleeding, dizziness, or jaundice.
BRINZOLAMIDE-1%W/VDisorders of porphyrin and bilirubin metabolism
Severe
How does the disease interact with Brinzagan Ophthalmic Suspension 5 ml:
When sulfonamides are administered to the skin, eye, or mucosal membranes, they may be absorbed systemically. Patients with porphyria should use topical sulfonamide therapy with caution because these medications can cause an acute attack. Patients with porphyria are thought to be contraindicated for oral sulfonamide usage.
How to manage the interaction:
Therapy should be administered cautiously in patients with porphyria, since it may precipitate an acute attack.
When sulfonamides are administered to the skin, eye, or mucosal membranes, they may be absorbed systemically. Patients with porphyria should use topical sulfonamide therapy with caution because these medications can cause an acute attack. Patients with porphyria are thought to be contraindicated for oral sulfonamide usage.
How to manage the interaction:
Therapy should be administered cautiously in patients with porphyria, since it may precipitate an acute attack.
BRINZOLAMIDE-1%W/VOther abnormal findings in urine
Moderate
How does the disease interact with Brinzagan Ophthalmic Suspension 5 ml:
When sulfonamides are administered to the skin, eye, or mucosal membranes, they may be absorbed systemically. Due to the sulfonamide and/or its N4-acetyl metabolite precipitating in the urinary tract, the usage of sulfonamides has been linked to crystalluria. There have been reports of renal toxicity, including hematuria, proteinuria, increased BUN and creatinine, uro- and nephrolithiasis, nephritis, toxic nephrosis, and more. During the use of sulfonamides, hydration and sufficient urine output (> 1.5 L/day) should be maintained. Patients who are dehydrated (for instance, as a result of severe diarrhoea or vomiting) may be more vulnerable to developing crystalluria and lithiasis, thus they should be encouraged to drink more liquids.
How to manage the interaction:
Dehydrated patients may be at increased risk for the development of crystalluria and lithiasis (formation of stones). Therefore, consume additional amounts of liquid. Hydration and adequate urinary output (> 1.5 L/day) should be maintained during administration of the medicine. Renal function tests and urinalysis should be performed regularly during prolonged therapy (> 2 weeks).
When sulfonamides are administered to the skin, eye, or mucosal membranes, they may be absorbed systemically. Due to the sulfonamide and/or its N4-acetyl metabolite precipitating in the urinary tract, the usage of sulfonamides has been linked to crystalluria. There have been reports of renal toxicity, including hematuria, proteinuria, increased BUN and creatinine, uro- and nephrolithiasis, nephritis, toxic nephrosis, and more. During the use of sulfonamides, hydration and sufficient urine output (> 1.5 L/day) should be maintained. Patients who are dehydrated (for instance, as a result of severe diarrhoea or vomiting) may be more vulnerable to developing crystalluria and lithiasis, thus they should be encouraged to drink more liquids.
How to manage the interaction:
Dehydrated patients may be at increased risk for the development of crystalluria and lithiasis (formation of stones). Therefore, consume additional amounts of liquid. Hydration and adequate urinary output (> 1.5 L/day) should be maintained during administration of the medicine. Renal function tests and urinalysis should be performed regularly during prolonged therapy (> 2 weeks).
BRINZOLAMIDE-1%W/VOther diseases of liver
Moderate
How does the disease interact with Brinzagan Ophthalmic Suspension 5 ml:
Rarely have individuals using sulfonamides reported experiencing hepatotoxicity, including jaundice, diffuse hepatocellular necrosis, hypersensitivity hepatitis, and hepatic failure.
How to manage the interaction:
Therapy should be administered cautiously in patients with liver disease.
Rarely have individuals using sulfonamides reported experiencing hepatotoxicity, including jaundice, diffuse hepatocellular necrosis, hypersensitivity hepatitis, and hepatic failure.
How to manage the interaction:
Therapy should be administered cautiously in patients with liver disease.
BRINZOLAMIDE-1%W/VOther disorders of kidney and ureter, not elsewhere classified
Moderate
How does the disease interact with Brinzagan Ophthalmic Suspension 5 ml:
Sulfonamide side effects may be more likely to occur in those with renal impairment because of decreased medication clearance. Sulfonamides can also result in toxic nephrosis, hematuria, proteinuria, increased BUN, and creatinine levels in addition to renal damage related to crystalluria.
How to manage the interaction:
Hydration and adequate urinary output (> 1.5 L/day) should be maintained during administration of the medicine in patients with kidney dysfunction. Renal function tests and urinalysis should be performed regularly during prolonged therapy (> 2 weeks).
Sulfonamide side effects may be more likely to occur in those with renal impairment because of decreased medication clearance. Sulfonamides can also result in toxic nephrosis, hematuria, proteinuria, increased BUN, and creatinine levels in addition to renal damage related to crystalluria.
How to manage the interaction:
Hydration and adequate urinary output (> 1.5 L/day) should be maintained during administration of the medicine in patients with kidney dysfunction. Renal function tests and urinalysis should be performed regularly during prolonged therapy (> 2 weeks).
BRINZOLAMIDE-1%W/VOther abnormal findings in urine
Moderate
How does the disease interact with Brinzagan Ophthalmic Suspension 5 ml:
When sulfonamides are administered to the skin, eye, or mucosal membranes, they may be absorbed systemically. Hematologic toxicity has been linked to the usage of sulfonamides.
How to manage the interaction:
A urinary output of at least 1.5 L/day should be maintained during therapy. Renal function tests and urinalysis should be performed regularly during prolonged therapy (> 2 weeks).
When sulfonamides are administered to the skin, eye, or mucosal membranes, they may be absorbed systemically. Hematologic toxicity has been linked to the usage of sulfonamides.
How to manage the interaction:
A urinary output of at least 1.5 L/day should be maintained during therapy. Renal function tests and urinalysis should be performed regularly during prolonged therapy (> 2 weeks).
Author Details
